State of Medtech

State of Medtech is the #1 podcast in medtech and medical devices. Hosted by Omar M. Khateeb, we go inside the business and science of healthcare innovation—with unfiltered interviews from top investors, startup founders, and industry leaders. Each week, we feature candid interviews with: 💼 Top medtech investors & VCs 🧠 Founders of disruptive medical device startups 🧬 Clinicians & industry leaders shaping the future of medicine From go-to-market to M&A, AI to surgical robotics, this is your edge for scaling, funding, and selling in medtech. New episodes weekly.

State of Medtech is a health podcast hosted by Unknown Host, with 419 episodes on record and a Required Pod Score of 80.

Unknown Host hosts State of Medtech, a health show with 419 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #419

  419.MedTech Venture Growth: Becoming Magnetic to Capital, Clinicians and Talent

  Sep 30, 202622 minS1

  In this solo episode, Omar Khateeb explains why MedTech founders should stop treating social media like traditional marketing and start using it as a market engineering tool to build investor demand, clinical credibility, strategic awareness, and talent attraction. Most companies begin outreach only when they need something. Investors hear from the company during a fundraise, physicians when adoption matters, recruiters when talent is needed, and strategics when partnerships or exits become relevant. Omar argues for a different model: build familiarity and belief before the ask arrives. That means aligning the founder’s vision, clinical progress, physician engagement, company milestones, PR, content, recruiting, and positioning so every signal reinforces the others. When an investor has watched a company for one or two years, the pitch deck is no longer the introduction. It becomes more evidence supporting a belief that has already formed. The same framework applies beyond fundraising. Physicians can become visible advocates, top executives can follow the company before considering a role, and strategic partners can understand the technology long before formal conversations begin. Omar calls this MedTech magnetism: consistent, credible signals that create market pull around a company. The goal is not more content. It is making real progress, leadership, innovation, and momentum easier for the market to understand, remember, and believe. The result is stronger familiarity before fundraising, hiring, adoption, or M&A talks DISCLAIMER This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified professionals before making decisions. EPISODE BREAKDOWN 00:00 Why MedTech Should Recruit Before It Needs Talent 01:02 Intro 01:23 Why MedTech Companies Need to Become Magnetic 02:44 Why MedTech Gets Social Media Wrong 03:44 Stop Chasing Investors and Start Building Belief 05:07 Why Great Technology Alone Is Not Enough 06:41 How Market Engineering Creates Magnetism 08:19 Why Investors Should Know You Before You Raise 10:06 How to Build Investor Familiarity Before Fundraising 11:29 Why Strategics Should Be Watching You Early 12:31 Finding the Physicians Who Drive Adoption 14:08 How Physician Validation Builds Market Credibility 15:15 How to Recruit Talent That Is Not Looking for a Job 16:51 Why You Should Recruit Before You Need People 17:15 How Social Media Can Strengthen Your Internal Team 18:27 How to Turn Market Signals Into Momentum 19:27 Why You Cannot Fake Company Magnetism 20:07 Why Belief Compounds Over Time 20:38 How MedTech Companies Become Magnetic 22:00 End Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis. SUBSCRIBE YouTube: https://www.youtube.com/@thestateofmedtech LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/ FOLLOW THE STATE OF MEDTECH LinkedIn: https://www.linkedin.com/company/thestateofmedtech/ Instagram: https://www.instagram.com/stateofmedtech/ TikTok: https://www.tiktok.com/@stateofmedtechpod X: https://x.com/stateofmedtech Facebook: https://www.facebook.com/stateofmedtech FOLLOW OMAR M. KHATEEB LinkedIn: https://www.linkedin.com/in/okhateeb/ Instagram: https://www.instagram.com/omar.m.khateeb/ TikTok: https://www.tiktok.com/@omar.m.khateeb X: https://x.com/OmarMKhateeb Facebook: https://www.facebook.com/OmarMKhateeb Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf Join Omar at Medtech CEO Camp in Boston: https://www.campcuriae.com/ #medtech #medtechinnovation #marketanalysis #medtechindustry #healthcareinnovation

  ListenShow Notes
• 

  Episode #418

  418. Venture Capital: Jenny Barba and Jeff Chu of Features Capital

  Sep 28, 20261h 5mS1

  In this episode, Omar Khateeb speaks with Jenny Barba and Jeff Chu, Co-Founders, Features Capital, about what makes an early-stage MedTech company investable before first-in-human data or meaningful revenue. Features Capital often invests $500,000 to $2 million at this stage. Jenny and Jeff explain why investors look beyond technology to founder execution, technical feasibility, clinical adoption, regulatory strategy, market understanding, capital efficiency, and milestones that can unlock future financing. They discuss why founders must know who buys, who pays, how clinicians adopt new technology, and what evidence supports commercialization. The conversation also covers patient enrollment, clinical-trial costs, fast followers, AI, sensors, implantable devices, neurotechnology, cardiovascular innovation, precision medicine, and minimally invasive therapies. DISCLAIMER This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified professionals. EPISODE BREAKDOWN 00:00 Meet Jenny Barba and Jeff Chu 01:17 Why Features Capital Was Built 02:00 How Features Capital Got Started 05:40 From Operator to Venture Investor 07:26 Supporting First-Time Founders 10:31 Operator and Finance Experience 11:11 How Early-Stage MedTech Should Pivot 13:18 What Makes a Founder Investable? 15:41 How Early Features Capital Invests 16:03 What Investors Need Pre-FIH 17:53 Why Clinical Strategy Starts Early 18:54 Why Clinical Trials Cost So Much 20:06 Check Size and Investment Strategy 21:02 Inside the Portfolio 23:21 Resonant Link and Implants 25:59 When Early MedTech Is Worth the Risk 27:03 Why Clinical Adoption Matters 27:57 When Is a Moonshot Worth the Risk? 29:16 Can Fast Followers Win? 31:08 Investing in Emerging Categories 32:41 Prana Surgical and Lung Cancer 34:05 Why Fast Followers Move Faster 35:29 Why Clinical Trials Cost More 36:04 Patient Enrollment Is the Bottleneck 37:51 Improving Patient Enrollment 39:38 Why Invest in MedTech Now? 41:51 Why MedTech Can Be More Defensible 43:36 MedTech vs Biotech Investment Risk 44:55 Why Commercial MedTech Is Sticky 45:29 PREXSIS and Medication Management 48:01 Which MedTech Sectors Stand Out? 48:56 Why Neurotech Is Emerging 49:23 Precision Medicine and Treatment 50:40 Where Investors and Founders Connect 52:11 Best MedTech Conferences 53:43 Robotics and Neuromodulation 54:24 Investments VCs Regret Passing On 55:35 Why Early MedTech Needs Venture Investing 56:18 Should First-Time Founders Stay CEO? 57:24 Why MedTech Needs Founder-Friendly Capital 57:59 The MedTech Unlocked Philosophy 59:43 Why Patient Impact Matters 01:00:35 Final Thoughts + Learn More 01:04:00 End Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis. SUBSCRIBE YouTube: https://www.youtube.com/@thestateofmedtech LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/ FOLLOW THE STATE OF MEDTECH LinkedIn: https://www.linkedin.com/company/thestateofmedtech/ Instagram: https://www.instagram.com/stateofmedtech/ TikTok: https://www.tiktok.com/@stateofmedtechpod X: https://x.com/stateofmedtech Facebook: https://www.facebook.com/stateofmedtech FOLLOW OMAR M. KHATEEB LinkedIn: https://www.linkedin.com/in/okhateeb/ Instagram: https://www.instagram.com/omar.m.khateeb/ TikTok: https://www.tiktok.com/@omar.m.khateeb X: https://x.com/OmarMKhateeb Facebook: https://www.facebook.com/OmarMKhateeb Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf Medtech CEO Camp in Boston: https://www.campcuriae.com/ #medtech #medtechindustry #venturecapital #medicaldevices #healthcareinnovation

  ListenShow Notes
• 

  Episode #417

  417. Unlocking Capital for Medtech Through QSBS

  Sep 23, 202630 minS1

  In this solo episode, Omar Khateeb explores why QSBS could become an overlooked capital formation tool in MedTech . QSBS was created to encourage investment in small American businesses, and Omar explains why it may fit MedTech investing well. Medical device companies often require years of engineering, clinical development, FDA review, reimbursement, manufacturing, and commercialization before investors see liquidity. Those timelines can put MedTech at a disadvantage against fast sectors. QSBS offers another way to think about that patience. Omar explains how qualifying investors may exclude portions of eligible federal capital gains after longer holding periods, while the 2025 changes raised the gross-assets threshold and exclusion limits. He covers domestic C corporations, newly issued shares, secondary transactions, asset thresholds, and investor communication . He also examines how QSBS benefits may potentially pass through certain fund structures to eligible LPs, making after-tax performance relevant to fund strategy. Omar also discusses Section 1045 , which may allow qualifying investors in certain early exits to move proceeds into another eligible investment, potentially recycling MedTech capital back into innovation. The core idea: MedTech asks investors to be patient, and QSBS may reward some of that patience . DISCLAIMER This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified professionals before making decisions. Episode Breakdown: 00:00 Why QSBS Could Bring More Capital Into MedTech 01:05 Intro + The MedTech Funding Opportunity 01:25 Why MedTech Has a Capital Problem 03:05 How QSBS Could Change MedTech Investing 05:08 What Is Qualified Small Business Stock? 06:42 How QSBS Can Improve Investor Returns 08:17 Why Founders Should Understand QSBS 09:06 The 2025 QSBS Changes That Matter 10:43 Why MedTech Timelines Could Become an Advantage 12:39 Does MedTech Actually Qualify for QSBS? 14:26 Medical Devices vs Healthcare Services 16:12 What MedTech Founders Need to Know About QSBS 17:45 Primary Shares vs Secondary Shares 19:03 The $75M Gross Assets Threshold Explained 20:20 How Founders Should Discuss QSBS With Investors 22:07 Why MedTech Venture Funds Should Care About QSBS 23:40 How QSBS Could Improve After-Tax Fund Returns 25:12 Could QSBS Make MedTech More Competitive for Capital? 25:48 What Happens If a MedTech Company Sells Early? 26:47 How Section 1045 Could Recycle Capital Into MedTech 27:20 Why QSBS Could Become a MedTech Capital Formation Tool 28:03 What Founders and Venture Funds Should Do Now 29:02 The Bigger Opportunity for MedTech Investing 30:11 End Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis. SUBSCRIBE YouTube: https://www.youtube.com/@thestateofmedtech LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/ FOLLOW THE STATE OF MEDTECH LinkedIn: https://www.linkedin.com/company/thestateofmedtech/ Instagram: https://www.instagram.com/stateofmedtech/ TikTok: https://www.tiktok.com/@stateofmedtechpod X: https://x.com/stateofmedtech Facebook: https://www.facebook.com/stateofmedtech FOLLOW OMAR M. KHATEEB LinkedIn: https://www.linkedin.com/in/okhateeb/ Instagram: https://www.instagram.com/omar.m.khateeb/ TikTok: https://www.tiktok.com/@omar.m.khateeb X: https://x.com/OmarMKhateeb Facebook: https://www.facebook.com/OmarMKhateeb Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf Medtech CEO Camp in Boston: https://www.campcuriae.com/ #medtech #medtechindustry #venturecapital #startupfunding #founder

  ListenShow Notes
• 

  Episode #393

  416. Venture Capital: Aneta Sottil of Andera Partners on Building MedTech Companies Investors Can Scale

  Sep 21, 20261h 5mS1

  In this episode, Omar Khateeb speaks with Aneta Sottil, Partner at Andera Partners, about what makes a MedTech company investable as the investment bar continues to rise. Aneta explains why early data is often no longer enough. Investors increasingly want stronger clinical validation, a clear path to market, reimbursement strategy, and proof that a technology can meaningfully improve patient care. She also explains the must-have vs nice-to-have test, why hardware matters, and why founder-investor alignment can shape commercialization and long-term value. The conversation covers MedTech M&A, strategic buyers, surgical robotics, BCI, neuromodulation, wearable cardiac technologies, BPH innovation, and the role of AI, data analytics, and predictive capabilities. DISCLAIMER This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified professionals before making decisions. Episode Breakdown: 00:00 AI and MedTech Investing 01:09 Meet Aneta Sottil 02:36 Andera’s MedTech Strategy 04:14 How Early Will Investors Go? 04:44 Early Stage Investing Has Changed 05:39 What MedTech Must Prove Today 06:47 Looking Beyond AI 08:12 Consolidation and MedTech 08:49 Fewer Strategic Buyers 10:48 Why Hardware Can Be Defensible 11:06 Why MedTech Must Integrate AI 12:01 Market Engineering and Growth 14:10 What Makes a Category Investable? 15:28 Must Have vs Nice to Have 17:28 MMI’s Microsurgery Robot 18:38 Value in Microsurgical Robotics 19:37 Are New Strategic Buyers Emerging? 20:45 Smaller Strategics and M&A 22:34 Is MedTech M&A Heating Up? 23:46 Boston Scientific and M&A 25:37 Neurotech and BCI 27:37 Why Neuromodulation Is Rising 28:49 Why Andera Invested in Spiro 30:10 De-Risking Early Stage MedTech 31:47 Neuromodulation for Asthma 33:12 Could Neuromodulation Transform Sleep? 34:48 Clinical Value vs Consumer Health 35:13 How Important Is Reimbursement? 37:34 Founder-Investor Alignment 38:13 How Founders Should Evaluate Investors 39:27 Painful Lessons From Investing 41:07 Commercialization Can Divide Teams 43:18 Supporting First-Time Founders 44:40 Experience vs Founder Conviction 45:54 Most Impactful MedTech Investments 47:09 Kestra and Wearable Defibrillators 49:39 Turning a Commercial Stall Into Growth 51:32 Why Patient Impact Matters 53:03 MedTech Innovations Investors Value 53:38 Exciting New Portfolio Companies 54:33 RiverMark and the BPH Opportunity 56:34 A Removable BPH Stent 58:36 Simple MedTech, Massive Value 59:03 Safety, Quality of Life and BPH 01:00:04 How Great Investors Keep Learning 01:00:51 Lessons From 25 Years of Investing 01:02:34 Staying Current on MedTech 01:03:02 Best MedTech Conferences 01:04:54 End Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis. SUBSCRIBE YouTube: https://www.youtube.com/@thestateofmedtech LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/ FOLLOW THE STATE OF MEDTECH LinkedIn: https://www.linkedin.com/company/thestateofmedtech/ Instagram: https://www.instagram.com/stateofmedtech/ TikTok: https://www.tiktok.com/@stateofmedtechpod X: https://x.com/stateofmedtech Facebook: https://www.facebook.com/stateofmedtech FOLLOW OMAR M. KHATEEB LinkedIn: https://www.linkedin.com/in/okhateeb/ Instagram: https://www.instagram.com/omar.m.khateeb/ TikTok: https://www.tiktok.com/@omar.m.khateeb X: https://x.com/OmarMKhateeb Facebook: https://www.facebook.com/OmarMKhateeb Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf Medtech CEO Camp: https://www.campcuriae.com/ #medtech #medtechinnovation #venturecapital #medicaldevices #healthcareinnovation

  ListenShow Notes
• 

  Episode #415

  415. Urology Venture Capital: AUA Nexus with Gavin Leonard of MedTech Syndicates and Steven Kaplan MD of the American Urological Association

  Sep 17, 20261h 2mS1

  Explore Showpad's VIP event, Excellence in the Field, in New York on October 8, 2026, for revenue leaders seeking practical AI and sales insights. Learn more . In this episode, Omar Khateeb speaks with Gavin Leonard, CEO of MedTech Syndicates, and Steven Kaplan, Director of the American Urological Association Innovation Nexus, to explore how clinical insight, capital and commercialization can move MedTech ideas toward patient impact. Steven shares how Nexus connects founders, clinicians, investors and strategics. Roughly 60 companies that presented over three years have collectively raised approximately $570 million. Gavin explains how clinicians can spot unmet needs and build investor confidence, sharing an example of a $4.2 million raise in 90 days. They also discuss why FDA approval is only the beginning. Reimbursement, coding, physician adoption and strategic fit shape commercial success. From bladder cancer and fertility to incontinence, remote diagnostics and AI, the conversation explores urology's opportunities and how medical societies can support innovation year-round. For founders, clinicians and investors, it offers lessons on bringing ideas to patients. DISCLAIMER This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions. Episode Breakdown: 00:00 Urology's Innovation Gap 01:23 The Future of Urology 03:35 Meet Dr. Steven Kaplan 04:50 Meet Gavin Leonard 05:53 Clinicians as Investors 07:02 New Funding Models 08:40 Creating AUA Innovation Nexus 10:18 Nexus Companies' $570M Raised 12:04 Market Engineering for MedTech 14:12 Why Urology? 16:32 Early-Stage Clinician Investors 20:15 When to Join Nexus 21:01 From Seed to Commercialization 25:14 How Nexus Works 26:46 Value Before Equity 27:45 Beyond FDA Approval 28:27 Building the Ecosystem 31:28 Rethinking MedTech Funding 33:28 Early-Stage Strategic Risk 35:56 Physicians Who Drive Adoption 37:44 Global Clinical Perspectives 39:48 Beyond Academic Centers 41:10 How Urologists Can Join 42:26 Inside a Nexus Event 44:51 Why Clinicians Attend 46:32 Year-Round Innovation 47:48 Validating Urology Startups 49:27 Rethinking Medical Meetings 51:46 Evolving Medical Societies 53:28 AUA's Innovation Approach 55:22 Urology's Biggest Opportunities 56:05 Bladder Cancer, Fertility and Incontinence 58:02 Remote Diagnostics 01:00:07 AI and Healthcare Efficiency 01:01:16 Final Thoughts and Resources 01:01:34 Outro 01:02:00 End Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis. SUBSCRIBE YouTube: https://www.youtube.com/@thestateofmedtech LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/ FOLLOW THE STATE OF MEDTECHLinkedIn: https://www.linkedin.com/company/thestateofmedtech/ Instagram: https://www.instagram.com/stateofmedtech/ TikTok: https://www.tiktok.com/@stateofmedtechpod X: https://x.com/stateofmedtech Facebook: https://www.facebook.com/stateofmedtech FOLLOW OMAR M. KHATEEB LinkedIn: https://www.linkedin.com/in/okhateeb/ Instagram: https://www.instagram.com/omar.m.khateeb/ TikTok: https://www.tiktok.com/@omar.m.khateeb X: https://x.com/OmarMKhateeb Facebook: https://www.facebook.com/OmarMKhateeb Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf Join Omar at Medtech CEO Camp in Boston https://www.campcuriae.com/ #medtech #urologyawareness #medicaldevices #healthcareinnovation #medtechindustry

  ListenShow Notes

Recent guests on State of Medtech. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.